Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 8%

Bulls say

Arvinas is a promising clinical-stage biotechnology company with a protein degradation platform that has the potential to revolutionize the treatment of debilitating and life-threatening diseases. With positive data for their lead candidate ARV-102, showing 72% reduction in LRRK2 levels in Parkinson's patients, and upcoming data for their other product candidates, Arvinas is positioned for potential success in the future. Furthermore, the company's strong financial position, with a partnership for ex-US commercialization and a diverse pipeline, adds to its appeal as a long-term investment option.

Bears say

Arvinas is facing strong competition in the market, especially in the LRRK2 inhibitor space with Biogen's BIIB122. Although ARV-102 shows slightly better results in terms of LRRK2 and urine BMP reductions, its sample size is smaller and it may not be enough to differentiate itself from other competitors. The positive results in CSF LRRK2 and pathway biomarkers reduction are consistent with prior healthy volunteer data, but the company still has a long way to go before validating the LRRK2 pathway broadly.

Arvinas Inc (ARVN) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 12 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.